Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Biomater ; 144: 183-194, 2022 05.
Article in English | MEDLINE | ID: mdl-35331938

ABSTRACT

The treatment of chronic Achilles tendonitis (AT) often requires prolonged therapy and invasive therapeutic methods such as surgery or therapeutic endoscopy. To prevent the progression of chronic AT, excessive inflammation must be alleviated at an early stage. Corticosteroids or nonsteroidal anti-inflammatory drugs are generally prescribed to control inflammation; however, the high doses and long therapeutic periods required may lead to serious side effects. Herein, a local injectable poly(organophosphazene) (PPZ) - celecoxib (CXB) nanoparticle (PCNP) hydrogel system with long-term anti-inflammatory effects was developed for the treatment of tendonitis. The amphiphilic structure and thermosensitive mechanical properties of PPZ means that the hydrophobic CXB can be easily incorporated into the hydrophobic core to form PCNP at 4 °C. Following the injection of PCNP into the AT, PCNP hydrogel formed at body temperature and induced long-term local anti-inflammatory effects via sustained release of the PCNP. The therapeutic effects of the injectable PCNP system can alleviate excessive inflammation during the early stages of tissue damage and boost tissue regeneration. This study suggests that PCNP has significant potential as a long-term anti-inflammatory agent through sustained nonsteroidal anti-inflammatory drugs (NSAIDs) delivery and tissue regeneration boosting. STATEMENT OF SIGNIFICANCE: In the treatment of Achilles tendinitis, a long-term anti-inflammatory effect is needed to alleviate excessive inflammation and induce regeneration of the damaged Achilles tendon. Injectable poly(organophosphazene)(PPZ)-celecoxib(CXB) nanoparticles (PCNP) generated a long-term, localized-anti-inflammatory effect in the injected region, which successfully induced the expression of anti-inflammatory cytokines and suppressed pro-inflammatory cytokines, while the PCNPs degraded completely. Accordingly, regeneration of the damaged Achilles tendon was achieved through the long-term anti-inflammatory effect induced by a single PCNP injection. The PCNP system therefore has great potential in long-term NSAIDs delivery for various tissue engineering applications.


Subject(s)
Achilles Tendon , Nanoparticles , Tendinopathy , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal , Celecoxib/pharmacology , Celecoxib/therapeutic use , Cytokines/pharmacology , Humans , Hydrogels/chemistry , Inflammation/drug therapy , Nanoparticles/chemistry , Nanoparticles/therapeutic use , Tendinopathy/drug therapy
2.
Bioact Mater ; 7: 14-25, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34466714

ABSTRACT

Treatment of osteoarthritis (OA) by administration of corticosteroids is a commonly used method in clinics using anti-inflammatory medicine. Oral administration or intra-articular injection of corticosteroids can reduce the pain and progress of cartilage degeneration, but they are usually insufficient to show local and long-term anti-inflammatory effects because of their fast clearance in the body. In this study, we suggest an injectable anti-OA drug depot system for sustained drug release that provides long-term effective therapeutic advantages. Amphiphilic poly(organophosphazene), which has temperature-dependent nanoparticle forming and sol-gel transition behaviors when dissolved in aqueous solution, was synthesized for triamcinolone acetonide (TCA) delivery. Because hydrophobic parts of the polymer can interact with hydrophobic parts of the TCA, the TCA was encapsulated into the self-assembled polymeric nanoparticles. The TCA-encapsulated polymeric nanoparticles (TePNs) were well dispersed in an aqueous solution below room temperature so that they can be easily injected as a sol state into an intra-articular region. However, the TePNs solution transforms immediately to a viscose 3D hydrogel like a synovial fluid in the intra-articular region via the conducted body temperature. An in vitro TCA release study showed sustained TCA release for six weeks. One-time injection of the TePN hydrogel system in an early stage of OA-induced rat model showed a great inhibition effect against further OA progression. The OA-induced knees completely recovered as a healthy cartilage without any abnormal symptoms.

3.
ACS Appl Mater Interfaces ; 11(17): 15201-15211, 2019 May 01.
Article in English | MEDLINE | ID: mdl-30945843

ABSTRACT

Daily treatment of diabetes to stabilize blood glucose level poses a challenge for patients with diabetes mellitus. Diabetes is a long-term metabolic disorder, and the treatment lasts for the rest of the patient's life after diagnosis. We presented a new injectable hydrogel depot system using exendin 4 (Ex-4) interactive and complex forming polymeric ionic-nano-particles for long-term antidiabetes treatment. Protamine-conjugated polymer (ProCP) was developed to form ionic-nano-complexes with Ex-4, as the amino-group-rich protamine and the negatively charged Ex-4 ( pI: 4.86) interact with each other due to their opposite electric charges in physiological conditions. Morphologically, the ProCP were nanoparticles in aqueous condition (10 wt % of ProCP in phosphate-buffered solution, <25 °C) and formed condensed ionic- and nano-complexes with Ex-4. The complexes formed a bulk hydrogel when exposed to body temperature. A slow release of the Ex-4/ProCP ionic-nano-complexes occurred from the hydrogel depot, followed by Ex-4 dissociation from the ionic-nano-complexes and hydrolysis of ProCP. Given that the Ex-4 release occurs after the complex releases from the hydrogel, the periods of Ex-4 release and hydrogel maintenance may be similar. The present system showed a considerably prolonged Ex-4 release. Additionally, it showed potential as a long-term effective and reproducible antidiabetes treatment.


Subject(s)
Exenatide/chemistry , Hydrogels/chemistry , Hypoglycemic Agents/chemistry , Nanostructures/chemistry , Polymers/chemistry , Animals , Cell Survival/drug effects , Delayed-Action Preparations , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/veterinary , Exenatide/pharmacokinetics , Exenatide/therapeutic use , Half-Life , Hypoglycemic Agents/pharmacokinetics , Hypoglycemic Agents/therapeutic use , Injections, Subcutaneous , Ions/chemistry , Male , Mice , Mice, Nude , NIH 3T3 Cells , Optical Imaging , Polymers/toxicity , Protamines/chemistry , Rats , Rats, Sprague-Dawley
4.
J Biomed Mater Res B Appl Biomater ; 106(2): 751-759, 2018 02.
Article in English | MEDLINE | ID: mdl-28334520

ABSTRACT

An injectable hydrogel system with sustained bone morphogenetic protein 2 (BMP-2) release ability was developed for vertical bone regeneration at peri-implant sites and enhanced osseointegration of dental implants. In three young male beagle dogs, a pair of defects was created on both sides of the mandibular bone. Next, two implants were transplanted into each defect. In situ gelling polymer solutions with or without BMP-2 were applied to cover the implants and mandibular defects. The effects of the in situ gelling and sustained BMP-2 releasing (IGSR) hydrogel system on peri-implant bone regeneration were evaluated by radiologic examination, micro-computed tomography, and histomorphometric analysis. Twelve weeks after the treatment, significant bone generation at the peri-implant site occurred following BMP-2/IGSR hydrogel treatment. Bone volume and mineral density were increased by 1.7- and 1.3-fold, respectively (p < 0.01 and 0.05 vs. control, respectively) for the BMP-2/IGSR hydrogel system. And, 0.57-0.31 mm vertical bone generation was observed at the peri-implant site for the BMP-2/IGSR hydrogel system, while rare vertical bone generation occurred in the control group. The BMP-2/IGSR hydrogel system significantly increased bone to implant contact % between induced bone and existing bone (p < 0.05 and 0.01 vs. control). These vertical bone regeneration and higher osseointegration levels demonstrated the effectiveness of the BMP-2/IGSR hydrogel system. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 751-759, 2018.


Subject(s)
Bone Morphogenetic Protein 2 , Bone Regeneration/drug effects , Hydrogels , Mandible/metabolism , Mandibular Injuries/therapy , Organophosphorus Compounds , Polymers , Animals , Bone Morphogenetic Protein 2/chemistry , Bone Morphogenetic Protein 2/pharmacology , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacology , Disease Models, Animal , Dogs , Hydrogels/chemistry , Hydrogels/pharmacology , Male , Mandible/pathology , Mandibular Injuries/metabolism , Mandibular Injuries/pathology , Organophosphorus Compounds/chemistry , Organophosphorus Compounds/pharmacology , Polymers/chemistry , Polymers/pharmacology
5.
Biomaterials ; 122: 91-104, 2017 04.
Article in English | MEDLINE | ID: mdl-28110173

ABSTRACT

For a substance to be used as a drug delivery carrier and tissue inducible material for a target disease, its drug release rate and physical properties should be optimized to facilitate the healing process. We developed multi-tunable hydrogel systems with various physical properties and release behaviors to determine the optimal conditions for bone regeneration. Five injectable poly(phosphazene) hydrogels were developed with different types and amounts of anionic side-chains. The five polymer hydrogels showed considerably different in vitro and in vivo performances for sol-gel phase transition, dissolution/degradation, water uptake, and pore size. Furthermore, bone morphogenetic protein-2 (BMP-2) was loaded into the polymer hydrogels by forming nano-sized ionic-complexes with each polymer. The five types of nanocomplex hydrogels showed completely different BMP-2 release rates. By administering each nanocomplex hydrogel to mouse calvarial, we identified the most adapted nanocomplex hydrogel system for effective bone regeneration. The BMP-2 release rate was the most important factor in effective bone regeneration. Finally, the bone regeneration effect of the optimized hydrogel system was investigated in a critical-sized calvarial defect model.


Subject(s)
Absorbable Implants , Bone Morphogenetic Protein 2/administration & dosage , Bone Regeneration/physiology , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/chemistry , Hydrogels/chemistry , Skull Fractures/drug therapy , Animals , Bone Morphogenetic Protein 2/chemistry , Bone Regeneration/drug effects , Diffusion , Hydrogels/administration & dosage , Injections , Male , Mice , Mice, Inbred C57BL , Nanocapsules/administration & dosage , Nanocapsules/chemistry , Skull Fractures/pathology , Treatment Outcome
6.
J Control Release ; 209: 67-76, 2015 Jul 10.
Article in English | MEDLINE | ID: mdl-25910579

ABSTRACT

Localized and continuous osteogenic stimulation to defected sites is required for effective bone regeneration. Here, we suggest an injectable and sustained bone morphogenetic protein-2 (BMP-2) release system using thermosensitive polymeric nanoparticles bearing dual interacting forces with BMP-2. For sustained BMP-2 release, hydrophobic and ionic interactions were introduced to thermosensitive poly(phosphazene). Hydrophobic isoleucine ethyl ester and hydrophilic poly-ethylene glycol were mainly substituted to the poly(phosphazene) back bone for amphiphilicity and hydrophobic interaction with BMP-2. Carboxylic acid moiety was additionally substituted to the back bone for ionic interaction with BMP-2. These dual interacting polymeric nanoparticles (D-NPs) formed compact nanocomplexes with BMP-2. The aqueous solution of BMP-2/D-NP nanocomplexes was transformed to hydrogel when the temperature of the solution increased. Loaded BMP-2 was sustain-released for three weeks from the BMP-2/D-NP nanocomplex hydrogel. The extended BMP-2 exposure caused higher osteocalcin secretion in C2C12 cells. Significant bone generations were observed at the target site by single injection of BMP-2/D-NP nanocomplexes in vivo.


Subject(s)
Bone Morphogenetic Protein 2/administration & dosage , Delayed-Action Preparations/administration & dosage , Hydrogels/administration & dosage , Nanoparticles/administration & dosage , Animals , Bone Morphogenetic Protein 2/chemistry , Bone Morphogenetic Protein 2/pharmacology , Bone Regeneration/drug effects , Cell Line , Cell Survival/drug effects , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacology , Drug Liberation , Hydrogels/chemistry , Hydrogels/pharmacology , Injections , Male , Mice , Mice, Inbred C57BL , NIH 3T3 Cells , Nanoparticles/chemistry , Organophosphorus Compounds/chemistry , Osteocalcin/metabolism , Polymers/chemistry
7.
Biomaterials ; 34(4): 1327-36, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23149013

ABSTRACT

A dual ionic interaction system composed of a positively charged polyelectrolyte complex (PEC) containing human growth hormone (hGH) and anionic thermosensitive hydrogel has been suggested for sustained delivery of bioactive hGH. The PEC was prepared by ionic interaction between negatively charged hGH and positively charged protamine sulfate (PS) to suppress diffusion of hGH. Moreover, we loaded the positively charged PEC into an anionic, injectable, and thermosensitive poly(organophosphazene) hydrogel to enhance sustained release of hGH by dual ionic interactions. PS formed a spherical complex with hGH, and their ionic interaction grew stronger with increasing amounts of PS. From a weight ratio of 0.5, the PS/hGH complex had a size and zeta-potential that were constantly maintained around 500 nm and +8 mV, respectively, in 0.9% NaCl. The PEC-loaded hydrogels suppressed the initial burst release of hGH and extended the release period in vitro and in vivo. In a pharmacokinetic study in rats, the PEC-loaded anionic hydrogel extended half-life 13-fold with similar area under the curve (AUC) compared to hGH solution. Furthermore, single injection of PEC-loaded anionic hydrogel showed a more increased growth rate than daily injection of hGH solution for 7 days in hypophysectomized rats, demonstrating its potential as an injectable, sustained delivery system that can release bioactive hGH.


Subject(s)
Body Weight/drug effects , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/chemistry , Human Growth Hormone/administration & dosage , Human Growth Hormone/chemistry , Hydrogels/chemistry , Ionic Liquids/chemistry , Animals , Diffusion , Electrolytes/chemistry , Injections , Male , Rats, Sprague-Dawley , Temperature , Treatment Outcome
8.
Biomaterials ; 32(32): 8271-80, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21839508

ABSTRACT

We have endeavored to develop injectable, thermosensitive, biodegradable hydrogels that prolong human growth hormone (hGH) release, improving bioavailability through introducing balanced ionic interactions. Cationic poly(organophosphazene)-polyethylenimine (PEI, 1.8 kDa) conjugate hydrogels were synthesized as those hydrogels for sustained delivery of anionic hGH with proper ionic strength of association/dissociation. We have additionally prepared different chain lengths of α-amino-ω-methoxy-poly(ethylene glycol) (AMPEG550 and AMPEG750) for the synthesis of conjugates as a means to control hydrogel degradation rates. All Aqueous solutions of PEI-conjugates became hydrogels hydrolyzable in proportion to AMPEG molecular weight at body temperature; these PEI-conjugates complexed with hGH and extended hGH release in vitro. In pharmacokinetic studies of hGH behavior in SD rats, hydrogels of PEI-conjugate/hGH complexes could suppress the initial burst-phase, and extend the duration, of release, as well as increasing of area under the curve (AUC) compared to controls including hGH solution or non-ionic hydrogel. In a hypophysectomized rat model, the biological efficacy of hGH delivered from PEI-conjugate/hGH complex hydrogels was equivalent to that from daily administration over four days based on body weight gain and width of the tibial growth plate. These results suggest that ionic, thermosensitive, poly(organophosphazene)-PEI-conjugate hydrogel demonstrates potential as an injectable depot for sustained delivery of bioavailable hGH.


Subject(s)
Human Growth Hormone/pharmacology , Human Growth Hormone/pharmacokinetics , Hydrogels/chemistry , Organophosphorus Compounds/chemistry , Polyethyleneimine/analogs & derivatives , Temperature , Animals , Biological Availability , Human Growth Hormone/administration & dosage , Humans , Hydrogen-Ion Concentration/drug effects , Hypophysectomy , Injections , Injections, Subcutaneous , Ions , Magnetic Resonance Spectroscopy , Male , Molecular Weight , Organophosphorus Compounds/chemical synthesis , Particle Size , Polyethyleneimine/chemical synthesis , Polyethyleneimine/chemistry , Rats , Rats, Sprague-Dawley , Spectrophotometry, Infrared , Time Factors , Viscosity/drug effects , Weight Gain/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...